China's 111 Inc. Gets Buyout Proposal From Co-Founders in Going-Private Push
111 Inc. (YI) reports Q2 2026 results with widened net loss, a shift to asset-light model, and an unsolicited $4.52/ADS privatization bid.
Stocks · News reference
111 Inc.'s Board Receives Going-Private Proposal From Co-Founders And Huadeng Tech BioArray Ventures At $4.52 Per ADS
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Earnings Scheduled For September 17, 2026
Companies Reporting Before The Bell • 111 (NASDAQ:YI) is projected to report earnings for its second quarter. • Innate Pharma (NASDAQ:IPHA) is projected to report quarterly loss at $0.16 per share on revenue of $9.10
111 Q2 Adj. EPS $(0.60) Down From $(0.40) YoY, Sales $338.995M Down From $447.507M YoY
111 (NASDAQ:YI) reported quarterly losses of $(0.60) per share. This is a 50 percent decrease over losses of $(0.40) per share from the same period last year. The company reported $338.995 million in sales this